【摘 要】
：
An approach to inhibit proliferation and increase cell death in breast cancer cell lines has given hope for the development of a new class of anticancer drugs.These new class of drugs are activators o
【机 构】
：
Yong Loo Lin School of Medicine National University of Singapore Singapore
【出 处】
：
(BITs 3rd Annual World Cancer Congress-2010, Breast Cancer C
论文部分内容阅读
An approach to inhibit proliferation and increase cell death in breast cancer cell lines has given hope for the development of a new class of anticancer drugs.These new class of drugs are activators of peroxisome proliferator-activated receptor gamma (PPARy).In addition to its endogenous ligand (15dPGJ2), several synthetic thiazolidinedione ligands (rosiglitazone and pioglitazone) are already in clinical use for the treatment of type 2 diabetes.Breast cancer cells express high levels of PPARγ, whereas normal breast cells express only a low level of this receptor.This suggested a possible role for active PPARγ as an anti-tumor agent in breast cancer.Recent studies report siRNA-suppression of mitochondrial manganese-dependent superoxide dismutase (MnSOD) expression leads to decrease in breast cancer cells invasive property and cells sensitization to anti-cancer drugs.
其他文献
Background: Bevaeizumab is a monoclonal antibody currently used for the treatment of colorectal cancer.It works by preventing the formation of new blood vessels (angiogenesis).The drug has been shown
Women with a family history of breast cancer who are diagnosed with breast cancer are often counseled to undergo prophylactic mastectomy as part of their treatment for breast cancer.The majority of su
Tremendous strides have been made to improve survival of breast cancer patients.15% still die however.Each loss is painful for her and her family.Breast cancer patients with metastatic disease treated
In breast cancer patients, venous drainage of the breast may contain cells of immunological importance, tumor cells undergoing dissemination and other biological factors derived from the tumor microen
Accumulating evidence suggests that obesity is a high risk factor for breast cancer among post-menopausal women, which can at least partially be explained by the contribution of adipose tissue to loca
Estrogen receptor (ER) β remains is the most important marker of response to hormonal therapy in breast cancer.The role of its sister molecule, ERβ, is much less clear.ERβ exists as 5 functionally dis
We developed and validated a readily applicable, context-dependent, subcellular localization-, cDNA library-, and cell type-independent Retrovirus-based Mammalian Two Hybrid (ReMTH) screen method for
Breast cancer is a major killer of women world wide.Every year, 1,000,000 new cases are diagnosed, with 40,000 deaths in the United States.Many patients either do not respond to chemotherapy or lose t
The aim of the study was to derive gene expression signature of estrogen receptor status for Taiwanese breast cancer patients.Estrogen receptor status is by far the most important prognostic and predi
Risk factors for pre-and postmenopausal breast cancer differ.Known and suspected risk factors for premenopausal breast cancer include high levels ofprolactin, IGF-1 and testosterone.Hormone levels dep